StachyoseCAS# 10094-58-3 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 10094-58-3 | SDF | Download SDF |
| PubChem ID | 439531 | Appearance | Powder |
| Formula | C24H42O21 | M.Wt | 666.57 |
| Type of Compound | Miscellaneous | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2S,3R,4S,5R,6R)-2-[[(2R,3R,4S,5R,6S)-6-[[(2R,3S,4S,5R,6R)-6-[(2S,3S,4S,5R)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methoxy]-3,4,5-trihydroxyoxan-2-yl]methoxy]-6-(hydroxymethyl)oxane-3,4,5-triol | ||
| SMILES | C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)OCC3C(C(C(C(O3)OC4(C(C(C(O4)CO)O)O)CO)O)O)O)O)O)O)O)O)O)O | ||
| Standard InChIKey | UQZIYBXSHAGNOE-XNSRJBNMSA-N | ||
| Standard InChI | InChI=1S/C24H42O21/c25-1-6-10(28)14(32)17(35)21(41-6)39-3-8-11(29)15(33)18(36)22(42-8)40-4-9-12(30)16(34)19(37)23(43-9)45-24(5-27)20(38)13(31)7(2-26)44-24/h6-23,25-38H,1-5H2/t6-,7-,8-,9-,10+,11+,12-,13-,14+,15+,16+,17-,18-,19-,20+,21+,22+,23-,24+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Stachyose, as prebiotics, can prevent indirectly colon cancer cell growth by promoting the proliferation of probiotics or producing beneficial materials in the intestine.Stachyose inhibits Caco-2 cell proliferation and induces apoptosis in a dose-dependent manner. Stachyose with an RS3 carrier has better preventative effects on colitis than Stachyose alone in mice. |
| Targets | Bcl-2/Bax | P450 (e.g. CYP17) | Caspase | IL Receptor | TNF-α |
| In vitro | Stachyose-induced apoptosis of Caco-2 cells via the caspase-dependent mitochondrial pathway.[Pubmed: 25578308]Food Funct. 2015 Mar 11;6(3):765-71.Some studies have shown that Stachyose, as prebiotics, can prevent indirectly colon cancer cell growth by promoting the proliferation of probiotics or producing beneficial materials in the intestine. However, its direct inhibitory effects on cancer cells are still unclear. Thus, this study aims to investigate the direct inhibitory effect of Stachyose on human colon cancer cells and determine the molecular mechanism underlying this effect. |
| In vivo | Inhibitory effects of resistant starch (RS3) as a carrier for stachyose on dextran sulfate sodium-induced ulcerative colitis in C57BL/6 mice.[Pubmed: 24223664]Exp Ther Med. 2013 Nov;6(5):1312-1316.
|
| Kinase Assay | Study of influential factors on oligosaccharide formation by fructosyltransferase activity during stachyose hydrolysis by Pectinex ultra SP-L.[Pubmed: 21882802]J Agric Food Chem. 2011 Oct 12;59(19):10705-11.The influence of reaction conditions for oligosaccharide synthesis from Stachyose using a commercial enzymatic preparation from Aspergillus aculeatus (Pectinex Ultra SP-L) was studied. |
Stachyose Dilution Calculator
Stachyose Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.5002 mL | 7.5011 mL | 15.0022 mL | 30.0044 mL | 37.5054 mL |
| 5 mM | 0.3 mL | 1.5002 mL | 3.0004 mL | 6.0009 mL | 7.5011 mL |
| 10 mM | 0.15 mL | 0.7501 mL | 1.5002 mL | 3.0004 mL | 3.7505 mL |
| 50 mM | 0.03 mL | 0.15 mL | 0.3 mL | 0.6001 mL | 0.7501 mL |
| 100 mM | 0.015 mL | 0.075 mL | 0.15 mL | 0.3 mL | 0.3751 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Caulophyllumine A
Catalog No.:BCN7928
CAS No.:1009318-60-8
- AZD2014
Catalog No.:BCC3732
CAS No.:1009298-59-2
- AZD8055
Catalog No.:BCC3629
CAS No.:1009298-09-2
- Panamycin 607
Catalog No.:BCN1813
CAS No.:100905-89-3
- Piceatannol
Catalog No.:BCN5824
CAS No.:10083-24-6
- (RS)-CPP
Catalog No.:BCC6561
CAS No.:100828-16-8
- 4,4'-Bis(α,α-dimethylbenzyl)diphenylamine
Catalog No.:BCC8661
CAS No.:10081-67-1
- Chlorahololide C
Catalog No.:BCN7256
CAS No.:1007859-25-7
- (R)-5-Hydroxy-1,7-diphenyl-3-heptanone
Catalog No.:BCN3591
CAS No.:100761-20-4
- Ganoderic acid M
Catalog No.:BCN2871
CAS No.:100761-17-9
- 1-O-Deacetylkhayanolide E
Catalog No.:BCN5823
CAS No.:1007387-95-2
- CH5132799
Catalog No.:BCC4991
CAS No.:1007207-67-1
- 2,2-Bis(hydroxymethyl)butyric acid
Catalog No.:BCC8495
CAS No.:10097-02-6
- Rotundine
Catalog No.:BCN5983
CAS No.:10097-84-4
- Ebrotidine
Catalog No.:BCC1542
CAS No.:100981-43-9
- Thiamet G
Catalog No.:BCC4864
CAS No.:1009816-48-1
- NSC 687852 (b-AP15)
Catalog No.:BCC2389
CAS No.:1009817-63-3
- CX-4945 (Silmitasertib)
Catalog No.:BCC3693
CAS No.:1009820-21-6
- Levofloxacin
Catalog No.:BCC4791
CAS No.:100986-85-4
- CY 208-243
Catalog No.:BCC6991
CAS No.:100999-26-6
- Pyridostigmine Bromide
Catalog No.:BCC4579
CAS No.:101-26-8
- Hyoscyamine
Catalog No.:BCN1946
CAS No.:101-31-5
- Bis[4-(dimethylamino)phenyl]methane
Catalog No.:BCC8889
CAS No.:101-61-1
- MK-5108 (VX-689)
Catalog No.:BCC2176
CAS No.:1010085-13-8
Study of influential factors on oligosaccharide formation by fructosyltransferase activity during stachyose hydrolysis by Pectinex ultra SP-L.[Pubmed:21882802]
J Agric Food Chem. 2011 Oct 12;59(19):10705-11.
The influence of reaction conditions for oligosaccharide synthesis from Stachyose using a commercial enzymatic preparation from Aspergillus aculeatus (Pectinex Ultra SP-L) was studied. Oligosaccharides were analyzed by gas chromatography with flame ionization detection (GC-FID) and matrix-assisted laser desorption/ionization-time-of-flight-mass spectrometry (MALDI-TOF-MS). Galactosyl-melibiose (DP(3)) was synthesized as a result of fructosidase activity, whereas fructosyl-Stachyose (DP(5)) and difructosyl-Stachyose (DP(6)) were formed as a consequence of the fructosyltransferase activity of Pectinex Ultra SP-L. The optimal reaction conditions for the synthesis of penta- and hexasaccharides were 60 degrees C, pH 5.5, 600 mg/mL Stachyose, and 34 U/mL enzyme. Reaction time played an important role in oligosaccharide mixture composition constituted by 20% DP(5), 0.7% DP(6), 55% Stachyose, 21% galactosyl-melibiose, and 1% monosaccharides after 1 h and 16% DP(5), 4% DP(6), 27% Stachyose, 44% galactosyl-melibiose, and 2% monosaccharides after 3 h. In conclusion, Stachyose could be used as a substrate for the enzymatic synthesis of new oligosaccharides that may open new opportunities in the development of future prebiotics.
Stachyose-induced apoptosis of Caco-2 cells via the caspase-dependent mitochondrial pathway.[Pubmed:25578308]
Food Funct. 2015 Mar;6(3):765-71.
Some studies have shown that Stachyose, as prebiotics, can prevent indirectly colon cancer cell growth by promoting the proliferation of probiotics or producing beneficial materials in the intestine. However, its direct inhibitory effects on cancer cells are still unclear. Thus, this study aims to investigate the direct inhibitory effect of Stachyose on human colon cancer cells and determine the molecular mechanism underlying this effect. The MTT assay was used to assess the inhibitory effect of Stachyose on Caco-2 cells. Apoptosis and mitochondrial membrane potential (DeltaPsim) measurements were analyzed using flow cytometry. The activities and mRNA expressions of caspases 3 and 9 were determined using caspase assay kits and quantitative real-time polymerase chain reaction. The apoptotic protein expressions of Bcl-2, Bax, and cytochrome C (Cyt C) were detected through western blotting. Results showed that Stachyose inhibits Caco-2 cell proliferation and induces apoptosis in a dose-dependent manner. After pretreatment with 0.4, 0.8, 1.6 and 3.2 mg mL(-1) Stachyose, cell inhibitory rates of 15.31% +/- 3.20%, 28.45% +/- 2.10%, 40.23% +/- 5.70%, and 55.67% +/- 4.50% were respectively obtained. Compared with the control, decreases in DeltaPsim, increases in caspase 3 and 9 activities and mRNA expressions, down-regulation of Bcl-2 protein expression, up-regulation of the Bax protein and Cyt C release of Caco-2 cells were clearly observed upon exposure to different Stachyose concentrations. The inhibitory mechanism of Stachyose on Caco-2 cells involves the caspase-dependent mitochondrial apoptosis pathway.
Inhibitory effects of resistant starch (RS3) as a carrier for stachyose on dextran sulfate sodium-induced ulcerative colitis in C57BL/6 mice.[Pubmed:24223664]
Exp Ther Med. 2013 Nov;6(5):1312-1316.
The aim of this study was to determine the effects of resistant starch 3 (RS3) as a carrier for Stachyose on dextran sulfate sodium (DSS)-induced colitis in C57BL/6 mice. RS3 microspheres carrying Stachyose (RS3 + Stachyose) were produced and evaluated as a potentially improved colitis therapy for this study. The body weights of the mice treated with RS3 + Stachyose were higher compared with those of DSS-treated control mice. RS3 + Stachyose reduced the levels of the serum pro-inflammatory cytokines IL-6 and TNF-alpha to a greater extent compared with the same concentration of Stachyose combined with ordinary starch (Stachyose + starch). Histopathological examination of sections of colon tissues showed that the RS3 + Stachyose group recovered well from colitis; however, the tissue sections of the Stachyose + starch group presented necrosis to a more serious degree. These results suggest that Stachyose with an RS3 carrier has better preventative effects on colitis than Stachyose alone in mice.
